H Marie Loughran
Overview
Explore the profile of H Marie Loughran including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
141
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fluorinated Isoindolinone-Based Glucosylceramide Synthase Inhibitors with Low Human Dose Projections
Loughran H, Schirripa K, Roecker A, Breslin M, Tong L, Fillgrove K, et al.
ACS Med Chem Lett
. 2024 Jan;
15(1):123-131.
PMID: 38229758
Inhibition of glucosylceramide synthase (GCS) has been proposed as a therapeutic strategy for the treatment of Parkinson's Disease (PD), particularly in patients where glycosphingolipid accumulation and lysosomal impairment are thought...
2.
Roecker A, Schirripa K, Loughran H, Tong L, Liang T, Fillgrove K, et al.
ACS Med Chem Lett
. 2023 Feb;
14(2):146-155.
PMID: 36793422
Parkinson's disease is the second most prevalent progressive neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra. Loss-of-function mutations in GBA, the gene that encodes for...
3.
Bungard C, Williams P, Schulz J, Wiscount C, Holloway M, Loughran H, et al.
ACS Med Chem Lett
. 2017 Dec;
8(12):1292-1297.
PMID: 29259750
Using the HIV-1 protease binding mode of and as inspiration, a novel aspartate binding bicyclic piperazine sulfonamide core was designed and synthesized. The resulting HIV-1 protease inhibitor containing this core...
4.
Loughran H, Han Z, Wrobel J, Decker S, Ruthel G, Freedman B, et al.
Bioorg Med Chem Lett
. 2016 Jul;
26(15):3429-35.
PMID: 27377328
We prepared a series of quinoxalin-2-mercapto-acetyl-urea analogs and evaluated them for their ability to inhibit viral egress in our Marburg and Ebola VP40 VLP budding assays in HEK293T cells. We...
5.
Emert-Sedlak L, Loughran H, Shi H, Kulp 3rd J, Shu S, Zhao J, et al.
Bioorg Med Chem Lett
. 2016 Feb;
26(5):1480-1484.
PMID: 26852364
The HIV-1 Nef accessory factor enhances viral replication and promotes immune system evasion of HIV-infected cells, making it an attractive target for drug discovery. Recently we described a novel class...
6.
Rubin H, Selwood T, Yano T, Weaver D, Loughran H, Costanzo M, et al.
Bioorg Med Chem Lett
. 2014 Dec;
25(2):378-83.
PMID: 25496770
The Gram-negative bacterium Acinetobacter baumannii is an opportunistic pathogen in humans and infections are poorly treated by current therapy. Recent emergence of multi-drug resistant strains and the lack of new...
7.
Williams P, Staas D, Venkatraman S, Loughran H, Ruzek R, Booth T, et al.
Bioorg Med Chem Lett
. 2010 Sep;
20(22):6754-7.
PMID: 20869872
Optimization studies using an HIV RNase H active site inhibitor containing a 1-hydroxy-1,8-naphthyridin-2(1H)-one core identified 4-position substituents that provided several potent and selective inhibitors. The best compound was potent and...
8.
Su H, Yan Y, Sridhar Prasad G, Smith R, Daniels C, Abeywickrema P, et al.
J Virol
. 2010 May;
84(15):7625-33.
PMID: 20484498
HIV/AIDS continues to be a menace to public health. Several drugs currently on the market have successfully improved the ability to manage the viral burden in infected patients. However, new...